{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T06:25:39Z","timestamp":1795155939945,"version":"4.10.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.antiviral.2020.104858","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:13:35Z","timestamp":1594034015000},"page":"104858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-8176","authenticated-orcid":false,"given":"David W.","family":"Hawman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-227X","authenticated-orcid":false,"given":"Elaine","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-0115","authenticated-orcid":false,"given":"Glenn","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lovaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104858_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/medethics-2011-100107","article-title":"A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations","volume":"38","author":"Arda","year":"2012","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.antiviral.2020.104858_bib2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jinf.2009.08.017","article-title":"Response to Ergonul: scientific evidence versus personal beliefs in crimean-Congo haemorrhagic fever treatment","volume":"59","author":"Ascioglu","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2020.104858_bib3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jac\/dkr136","article-title":"Ribavirin for patients with Crimean\u2013Congo haemorrhagic fever: a systematic review and meta-analysis","volume":"66","author":"Ascioglu","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104858_bib4","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1128\/JVI.01383-10","article-title":"Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model","volume":"84","author":"Bente","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104858_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2007.09.010","article-title":"Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality","volume":"12","author":"\u00c7evik","year":"2008","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib9","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-018-25780-3","article-title":"Favipiravir (T-705) protects against Nipah virus infection in the hamster model","volume":"8","author":"Dawes","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104858_bib10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3201\/eid1311.070222","article-title":"Viral load as predictor of crimean-Congo hemorrhagic fever outcome","volume":"13","author":"Duh","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(06)70435-2","article-title":"Crimean-Congo haemorrhagic fever","volume":"6","author":"Ergonul","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jinf.2009.08.006","volume":"59","author":"Ergonul","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2020.104858_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijid.2014.08.016","article-title":"Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever","volume":"29","author":"Ergonul","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-0691.2006.01445.x","article-title":"Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited","volume":"12","author":"Ergonul","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2020.104858_bib15","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3201\/eid2409.171709","article-title":"Systematic review and meta-analysis of postexposure prophylaxis for crimean-Congo hemorrhagic fever virus among healthcare workers","volume":"24","author":"Ergonul","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib16","author":"Feldmann"},{"key":"10.1016\/j.antiviral.2020.104858_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104858_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.antiviral.2020.104858_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.07.003","article-title":"Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever","volume":"121","author":"Gowen","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002535","article-title":"Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques","volume":"15","author":"Guedj","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104858_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41564-018-0141-7","article-title":"A cynomolgus macaque model for Crimean-Congo haemorrhagic fever","volume":"3","author":"Haddock","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104858_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2015.12.006","article-title":"Crucial parameter of the outcome in Crimean Congo hemorrhagic fever: viral load","volume":"75","author":"Hasanoglu","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2020.104858_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2018.06.013","article-title":"Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice","volume":"157","author":"Hawman","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib25","article-title":"Ribavirin for treating Crimean Congo haemorrhagic fever","volume":"6","author":"Johnson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2020.104858_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcv.2009.11.007","article-title":"The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey","volume":"47","author":"Koksal","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2020.104858_bib27","article-title":"Use of favipiravir to treat Lassa virus infection in macaques","volume":"24","author":"Kyle","year":"2018","journal-title":"Emerg. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104858_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104858_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib31","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015"},{"key":"10.1016\/j.antiviral.2020.104858_bib32","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104858_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104858_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2334-10-207","article-title":"Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis","volume":"10","author":"Soares-Weiser","year":"2010","journal-title":"BMC Infect. Dis."},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2020.104858_bib35","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1093\/clinids\/11.Supplement_4.S794","article-title":"The clinical pathology of Crimean-Congo hemorrhagic fever","volume":"11","author":"Swanepoel","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104858_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2017.10.008","article-title":"Identification of 2\u2032-deoxy-2\u2032-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus","volume":"147","author":"Welch","year":"2017","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:15Z","timestamp":1759062735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"alternative-id":["S0166354220302722"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104858","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104858"}}